News >

Bekaii-Saab Highlights Emerging Treatments for Patients With mCRC

Caroline Seymour
Published: Friday, Jun 22, 2018

Tanios Bekaii-Saab, MD

Tanios Bekaii-Saab, MD
Dosing strategies and novel treatment regimens are 2 of many areas being explored in the colorectal cancer (CRC) eld, while paying close attention to molecular subgroups, explained Tanios Bekaii-Saab, MD.

State of the Science Summit,™ Bekaii-Saab, who chaired the meeting, outlined clinical trials that have defined the current landscape of mCRC and what research is underway.

OncLive: What is currently being discussed in refractory mCRC?

Bekaii-Saab: These patients go through first and second- line therapies, and sometimes through third-line therapy. The question becomes, “What do we do for patients beyond second-line therapy?” Previously, we had very few options, if any, for these patients. Now we have 2 oral options with regorafenib and TAS-102 (Lonsurf). These agents are different from each other. Regorafenib is a multikinase inhibitor; it’s a multitargeted agent. TAS-102 is a more traditional cytotoxic agent; it belongs to the family of fluoropyrimidines. It’s not 5-FU [5-fluorouracil] or capecitabine; it belongs to that family that seems to work when the others fail.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Individualizing Treatment After Second-Line Therapy for Patients With mCRCAug 29, 20191.0
Community Practice Connections™: Immunotherapeutic Strategies with the Potential to Transform Treatment for Genitourinary CancersAug 29, 20191.0
Publication Bottom Border
Border Publication